Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;12(3):195-201.
doi: 10.2174/1874467212666190111165015.

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

Pitchai Balakumar  1 , Nanjaian Mahadevan  2 , Ramanathan Sambathkumar  1
Affiliations
Review

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

Pitchai Balakumar et al. Curr Mol Pharmacol. 2019.

Abstract

Background: Diabetes mellitus and concomitant dyslipidemia, being referred to as 'diabetic dyslipidemia', are the foremost detrimental factors documented to play a pivotal role in cardiovascular illness. Diabetic dyslipidemia is associated with insulin resistance, high plasma triglyceride levels, low HDL-cholesterol concentration and elevated small dense LDL-cholesterol particles. Maintaining an optimal glucose and lipid levels in patients afflicted with diabetic dyslipidemia could be a major task that might require a well-planned diet-management system and regular physical activity, or otherwise an intake of combined antidiabetic and antihyperlipidemic medications. Synchronized treatment which efficiently controls insulin resistance-associated diabetes mellitus and co-existing dyslipidemia could indeed be a fascinating therapeutic option in the management of diabetic dyslipidemia. Peroxisome proliferator-activated receptors α/γ (PPARα/γ) dual agonists are such kind of drugs which possess therapeutic potentials to treat diabetic dyslipidemia. Nevertheless, PPARα/γ dual agonists like muraglitazar, naveglitazar, tesaglitazar, ragaglitazar and aleglitazar have been reported to have undesirable adverse effects, and their developments have been halted at various stages. On the other hand, a recently introduced PPARα/γ dual agonist, saroglitazar is an emerging therapeutic agent of glitazar class approved in India for the management of diabetic dyslipidemia, and its treatment has been reported to be generally safe and well tolerated.

Conclusion: Some additional and new compounds, at initial and preclinical stages, have been recently reported to possess PPARα/γ dual agonistic potentials with considerable therapeutic efficacy and reduced adverse profile. This review sheds light on the current status of various PPARα/γ dual agonists for the management of diabetic dyslipidemia.

Keywords: PPARα/γ dual agonists; adverse effects; cardiovascular events; diabetic dyslipidemia; insulin resistance; oedema..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Therapeutic rationale of PPARα/γ dual agonism for the management of diabetic dyslipidemia.
See this image and copyright information in PMC

References

    1. Chehade J.M., Gladysz M., Mooradian A.D. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327–339. - PubMed
    1. Chigurupati S., Dhanaraj S.A., Balakumar P. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance. Eur. J. Pharmacol. 2015;755:50–57. - PubMed
    1. Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004;53:S43–S50. - PubMed
    1. Balakumar P., Jagadeesh G. PPAR ligands and cardiovascular disorders: Friend or foe. Curr. Mol. Pharmacol. 2012;5:219–223. - PubMed
    1. Balakumar P., Rose M., Ganti S.S., Krishan P., Singh M. PPAR dual agonists: Are they opening Pandora’s Box? Pharmacol. Res. 2007;56:91–98. - PubMed

MeSH terms